Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Casi Pharmaceuticals Inc (CASI)

Casi Pharmaceuticals Inc (CASI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,552
  • Shares Outstanding, K 12,299
  • Annual Sales, $ 28,540 K
  • Annual Income, $ -39,260 K
  • EBIT $ -44 M
  • EBITDA $ -42 M
  • 60-Month Beta 0.91
  • Price/Sales 0.15
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.01
  • Most Recent Earnings $-0.67 on 11/14/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 685.34% (+286.88%)
  • Historical Volatility 387.50%
  • IV Percentile 91%
  • IV Rank 49.61%
  • IV High 1,329.79% on 05/16/25
  • IV Low 50.92% on 10/16/25
  • Expected Move (DTE 18) 0.0425 (20.48%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 251
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 115
  • Open Int (30-Day) 112
  • Expected Range 0.1650 to 0.2500

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 1
  • High Estimate -0.36
  • Low Estimate -0.36
  • Prior Year -0.79
  • Growth Rate Est. (year over year) +54.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2075 unch
on 02/25/26
1.0450 -80.14%
on 01/28/26
-0.7525 (-78.39%)
since 01/23/26
3-Month
0.2075 unch
on 02/25/26
1.2000 -82.71%
on 01/09/26
-0.9225 (-81.64%)
since 11/25/25
52-Week
0.2075 unch
on 02/25/26
3.0900 -93.28%
on 08/15/25
-2.1225 (-91.09%)
since 02/25/25

Most Recent Stories

More News
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish

The company said that its special committee of the board of directors will evaluate the proposed transaction.

CASI : 0.2075 (-74.06%)
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

BEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 0.2075 (-74.06%)
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...

CASI : 0.2075 (-74.06%)
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and...

CASI : 0.2075 (-74.06%)
Nasdaq Futures Fall as Micron’s Sales Outlook Disappoints, U.S. GDP Data and Nike Earnings in Focus

September Nasdaq 100 E-Mini futures (NQU24) are trending down -0.23% this morning as an underwhelming sales forecast from chipmaker Micron weighed on sentiment, while investors awaited a flurry of U.S....

WHR : 68.43 (+0.29%)
AAPL : 264.18 (-3.21%)
HMB.S.DX : 192.700 (-0.64%)
MKC : 71.04 (+2.57%)
NQU24 : 19,808.01s (-0.21%)
USB : 54.66 (-4.54%)
IP : 43.55 (+0.97%)
MU : 412.37 (-0.77%)
NKE : 62.18 (-2.77%)
CASI : 0.2075 (-74.06%)
LEVI : 22.16 (-1.77%)
AYI : 301.59 (-1.93%)
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 0.2075 (-74.06%)
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 0.2075 (-74.06%)
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing...

CASI : 0.2075 (-74.06%)
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

CASI : 0.2075 (-74.06%)
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...

CASI : 0.2075 (-74.06%)

Business Summary

CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic...

See More

Key Turning Points

3rd Resistance Point 0.4865
2nd Resistance Point 0.4307
1st Resistance Point 0.3191
Last Price 0.2075
1st Support Level 0.1517
2nd Support Level 0.0959
3rd Support Level N/A

See More

52-Week High 3.0900
Fibonacci 61.8% 1.9889
Fibonacci 50% 1.6487
Fibonacci 38.2% 1.3086
Last Price 0.2075
52-Week Low 0.2075

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar